MiCareo focus on precision medicine and liquid biopsy technology for rare cell isolation, such as circulating tumor cell and tumor-related immune cell. With a single device and from a single tube of blood, MiCareo’s technology can isolate and profile a single live cell and deliver both biological and genomic information. We offer a tool for drug developer and researcher to accelerate drug development and biomarker discovery, enabling patient selection and treatment monitoring for immuno- and targeted therapy.
2011 | Licensing of eDAR technology from University of Washington. |
2011 | MiCareo Taiwan is officially founded in Neihu, Taipei. |
2011 | Signed a contract with the Institute of Industrial Technology (ITRI) to conduct research and development of instrument prototypes. |
2012 | The first instrument prototype (open system). |
2013 | First clinical patient sample run on MiSelect Alpha. |
2015 | Microfluidic chip-SelectChip Dual developed and validated for enrichment and identification of rare cells. |
2016 | Integrated instrument-MiSelect R developed and validated. |
2017 | GMP certification for microfluidic chip manufacturing. |
2017 | Processed our 500th clinical patient sample. |
2019 | Commercial launch of the MiSelect R. |
2019 | Development of technology and product for single cell isolation and molecular analysis. |
2019 | Initiate and establish collaboration with pharmaceutical company and academic research center. |